The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects.

Abstract

OBJECTIVE:

To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day).

DESIGN:

A prospective, randomized, double-blind and placebo-controlled single-center trial.

SUBJECTS:

Twenty-eight healthy, obese subjects (16 women, 12 men; age 22-65 y; body mass index 27.7-38.7 kg/m2).

MEASUREMENTS:

Bodyweight, metabolic profile (including lipids), C-reactive protein (CRP) and soluble TNF alpha-receptor (sTNF-R) 55 and 75 levels.

RESULTS:

At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n = 14) and PEG-OB (n = 14) groups was observed. Also the changes in metabolic profile, CRP, sTNF-R55 and R75 concentrations between the two groups after 8 weeks of treatment did not differ.

CONCLUSION:

Weekly injection of 60 mg PEG-OB did not lead to additional weight loss after 8 weeks of treatment. Furthermore, PEG-OB administration did not affect the changes in metabolic profile and the inflammatory status of obese subjects.

• Authors: C J Hukshorn, F M H van Dielen, W A Buurman, M S Westerterp-Plantenga, L A Campfield, W H M Saris
• Journal: International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity (Int J Obes Relat Metab Disord) Vol. 26 Issue 4 Pg. 504-9 (Apr 2002) England
• PMID: 12075577 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Blood Glucose
• Insulin
• LEPR protein, human
• Leptin
• Placebos
• Receptors, Leptin
• Receptors, Tumor Necrosis Factor
• C-Reactive Protein

Topics

• Adolescent
• Adult
• Aged
• Blood Glucose (analysis)
• Body Mass Index
• Body Weight
• C-Reactive Protein (analysis)
• Double-Blind Method
• Female
• Humans
• Inflammation (blood, complications)
• Insulin (blood)
• Insulin Resistance
• Leptin (administration & dosage, blood, therapeutic use)
• Male
• Middle Aged
• Obesity (blood, complications, therapy)
• Placebos
• Prospective Studies
• Receptors, Leptin
• Receptors, Tumor Necrosis Factor (analysis)
• Weight Loss